rug-eluting stents (DES) have proved a seminal innovation for interventional cardiologists and patients with coronary artery disease alike. Proof of efficacy and safety in large patients groups has been provided by both meta-analyses of randomized trials and real-world observational studies. 1- 4 The long-term safety of DES has, however, been questioned several times, given the established presence of incomplete endothelial coverage, peri-stent endothelial dysfunction and inflammation. 5-8 Such phenomena could easily translate, especially over months or years after percutaneous coronary intervention (PCI), into adverse events such as stent thrombosis, delayed restenosis, acquired malapposition or aneurysm formation.
Article p 1704
A crucial problem in appraising the risk -benefit profile of the currently available DES and the quest for means to modify the biocompatibility of such devices is the paucity of suitable data from preclinical (ie, animal) models of DES implantation. This issue of the Journal provides an interesting experimental porcine study by Kubota et al, 9 in which 24 pigs underwent sirolimus-eluting stent implantation and were then treated with a calcium-channel blocker (CCB, azelnidipine), an angiotensin-receptor blocker (ARB, olmesartan), both or placebo. Hearts were harvested 4 weeks later, endotheliumdependent relaxation of the DES edges was examined using organ chamber, and inflammation was appraised with standard histology, scanning electron microscopy and immunohistochemistry. Endothelium-mediated vasodilation at the distal edge of the stent was significantly impaired compared with the intact site in the control group, but not in the group treated with azelnidipine and olmesartan. Similarly, inflammatory cell adhesion and expression of tumor necrosis factoralpha was significantly reduced by combination therapy with both azelnidipine and olmesartan.
The work of Kubota and associates importantly shows that some drugs, which could generically be called "cardio-protectors", belong to a group that may exert anti-inflammatory and endothelium-active actions, especially when associated 
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CCB and ARB for DES (Table) . The vascular actions of ARBs and CCBs are, in other words, synergistic rather than additive. Given that one of the main potential problems of DES is related to stent thrombosis, even a long time after stent implantation, because of the lack of re-endothelialization and the chronic inflammatory response induced by the polymer, finding pharmacological compounds that improve endothelial function and reduce the inflammatory response may have some very interesting clinical implications. The effect of angiotensin-converting enzyme inhibitors, ARBs and CCBs should actually come as no surprise as they are established modulators of endothelial function and subclinical inflammation in several settings, 10-12 but there are no studies on the value of the 2 classes of drugs, in association, after DES implantation. The major scientific merit of the study by Kubota and colleagues is thus to establish the superiority of combination therapy compared with monotherapy.
This work also has a number of limitations. The sample size is small, and the fact that the animals treated were not affected by atherosclerosis but had healthy coronary arteries limits external validity. In addition, an in vivo assessment of endothelial function (such as with acetylcholine infusion or pacing) could have further supported the authors' findings. Indeed, the very same use of an animal model, despite being scientifically sound, limits clinical applicability, and thus clinical studies are warranted to confirm or disprove these promising findings. For these reasons the results of the present study may not be applicable either to diseased animals or to humans in whom stents are typically implanted to treat atherosclerotic coronaries. Finally, there is still limited information on the pathophysiologic mechanism to explain why the combination of drugs was more effective than either alone.
In conclusion, this study reinforces the role of medical therapy to pharmacologically engineer endothelial function and the vessel's response to DES, whether we can already do it ourselves with CCBs and ARBs in real-world patients remains to be seen. Nonetheless, in subjects at high-risk of DES failure, such as those with coronary bifurcation lesions or small vessel disease, 13,14 and with concomitant indications for ARB and CCB therapy (eg, because of arterial hypertension), we can safely use these agents and be reasonably confident they will also improve the long-term outcome of DES implantation.
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